Healthpoint Biotherapeutics announces HP802-247 clinical trial results
HP802-247 is an investigational allogeneic living cell bioformulation that contains keratinocytes and fibroblasts currently under development for venous leg ulcers treatment. Healthpoint Biotherapeutics chief medical officer Bert Slade
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.